Clinical trial NCT00096915: Study Evaluating Darbepoetin Alfa in Subjects With Chronic Kidney Disease (CKD) Receiving Dialysis
Official title: A Multicenter, Single-Arm Study Evaluating Once Monthly Darbepoetin Alfa Dosing in Subjects With Chronic Kidney Disease (CKD) Receiving Dialysis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Kidney Disease
Chronic Kidney Disease
Keywords: chronic kidney disease, CKD
renal failure
anemia
hemodialysis
peritoneal dialysis
Aranesp®, Darbepoetin Alfa
Lead sponsor: Amgen
Sponsor class: INDUSTRY
First posted: 2004-11-18
Enrollment: 110
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The proposed study is designed to test a novel dosing paradigm that would facilitate the treatment of anemia in CKD patients on dialysis. Anemic patients on hemo and peritoneal dialysis who have achieved and maintained target hemoglobin (Hb) on every other week (Q2W) dosing of darbepoetin alfa will have the dosing interval extended to once monthly (QM) dosing.


Eligibility criteria: Inclusion Criteria:

* Diagnosis of chronic kidney disease (CKD) and receiving dialysis for \> 3 months before enrollment
* Clinically stable, in the judgment of the investigator
* Mean Hb \> 11.0 g/dL (110 g/L) to \< 13.0 g/dL (130 g/L)
* Transferrin saturation (Tsat) \> 19.5%
* Serum vitamin B12 and folate levels above the lower limit of the normal range
* Receiving stable Q2W IV or SC doses of Aranesp® (darbepoetin alfa). A stable dose is defined as less than or equal to 25% change in dose over the 6-week period immediately prior to enrollment and with no missed doses in this period

Exclusion Criteria:

* Scheduled to receive a kidney transplant
* Diastolic blood pressure greater than 110 mm Hg or systolic BP greater than 180 mm Hg during screening
* Acute myocardial ischemia
* Hospitalization for congestive heart failure, myocardial infarction, deep vein thrombosis, stroke or transient ischemic attack within 12 weeks before enrollment
* Parathyroid hormone (PTH) level greater than 1500 pg/mL (158.0 pmol/L)
* Major surgery within 12 weeks before enrollment (excluding vascular access surgery)
* Currently receiving antibiotic therapy for systemic infection
* Known positive HIV antibody or positive hepatitis B surface antigen
* Clinical evidence of current malignancy and/or receiving systemic chemotherapy/radiotherapy with the exception of basal cell or squamous cell carcinoma of the skin and cervical intraepithelial neoplasia
* Red blood cell (RBC) transfusions within 8 weeks before enrollment
* Androgen therapy within 8 weeks before enrollment - Systemic hematologic disease (e.g., sickle cell anemia, myelodysplastic syndromes, hematologic malignancy, myeloma, hemolytic anemia)
* Any disorder that may impact (in the judgment of the investigator) the ability to give informed consent for participation in this study
* Pregnant or breast-feeding women
* All subjects must practice adequate contraception (in the judgment of the investigator) throughout this trial
* Treatment with an investigational agent or device within 30 days before enrollment or scheduled to receive an investigational agent other than those specified by this protocol during the course of this study

Primary outcomes:
measure: The proportion of subjects on QM darbepoetin alfa dosing maintained with a mean Hb greater than or equal to 11.0 g/dL and less than or equal to 13.0 g/dL during the evaluation phase
timeFrame: entire study
Secondary outcomes:
measure: Hb values over the duration of the study
timeFrame: entire study
measure: Darbepoetin alfa doses over the duration of the study
timeFrame: entire study
measure: Frequency and relationship to treatment for adverse events and changes in laboratory parameters and blood pressure
timeFrame: entire study
Other outcomes:
Locations:
Study officials:
affiliation: Amgen
name: MD
role: STUDY_DIRECTOR
References: